Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394769 | 0.89 | CALCA (0.58) | CALCRLCALCA | |
| SCHEMBL1393840 | 0.85 | CALCA (0.60) | CALCRLCALCA | |
| SCHEMBL1393838 | 0.85 | CALCA (0.60) | CALCRLCALCA | |
| SCHEMBL12049267 | 0.84 | CALCA (0.59) | CALCRLCALCA | |
| SCHEMBL10153304 | 0.84 | CALCA (0.59) | CALCRLCALCA | |
| SCHEMBL10153387 | 0.84 | CALCA (0.59) | CALCRLCALCA | |
| SCHEMBL12049404 | 0.82 | CALCRL (0.60) | CALCRLCALCA | |
| SCHEMBL12048960 | 0.82 | CALCRL (0.56) | CALCRLCALCA | |
| SCHEMBL13034485 | 0.81 | CALCA (0.54) | CALCRLCALCA | |
| SCHEMBL3526238 | 0.81 | CALCA (0.54) | CALCRLCALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954268-B1 | SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-1954268-B1 | SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| US-8071772-B2 | Spirolactam bicyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071772-B2 | Spirolactam bicyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071772-B2 | Spirolactam bicyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090325991-A1 | Spirolactam Bicyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090325991-A1 | Spirolactam Bicyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090325991-A1 | Spirolactam Bicyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-12-31 | — | — | US | disclosed |
| WO-2007061696-A2 | SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325991-A1 | Spirolactam Bicyclic CGRP Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | CALCRL 2/4885CALCA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.